Valuation : Cara Therapeutics, Inc.

Market Cap 24.33M 20.99M 19.77M 18.02M 33.68M 2.3B 33.93M 234M 90.85M 1.18B 91.37M 89.37M 3.86B P/E 2023
-0.34x
P/E 2024 -0.39x
Enterprise Value 30.88M 26.64M 25.09M 22.86M 42.73M 2.92B 43.05M 297M 115M 1.49B 116M 113M 4.9B EV / Sales 2023
-0.82x
EV / Sales 2024 4.84x
Free-Float
-
Yield 2023 *
-
Yield 2024 -

Financials

2023 2024
Net sales 20.97M 18.09M 17.04M 15.53M 29.02M 1.98B 29.24M 202M 78.29M 1.01B 78.74M 77.02M 3.33B 7.14M 6.16M 5.8M 5.28M 9.88M 674M 9.95M 68.67M 26.65M 345M 26.8M 26.21M 1.13B
Net income -119M -102M -96.31M -87.75M -164M -11.2B -165M -1.14B -443M -5.72B -445M -435M -18.8B -70.87M -61.14M -57.59M -52.47M -98.08M -6.69B -98.82M -682M -265M -3.42B -266M -260M -11.24B
Net Debt -57.59M -49.68M -46.8M -42.64M -79.71M -5.44B -80.3M -554M -215M -2.78B -216M -212M -9.14B 6.54M 5.65M 5.32M 4.85M 9.06M 618M 9.13M 62.97M 24.44M 316M 24.58M 24.04M 1.04B
Logo Cara Therapeutics, Inc.
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Employees
-
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B